Enanta Pharmaceuticals, Inc. has announced that Jay R. Luly, Ph.D., will retire as President and Chief Executive Officer by February 1, 2027. This decision comes after 23 years of leadership at the company. Luly will continue to assist as a strategic advisor throughout the remainder of 2027 to ensure a smooth transition. The company has begun a search for his successor, considering both internal and external candidates.

In conjunction with Luly's retirement announcement, Enanta appointed Tara L. Kieffer, Ph.D., to the newly created position of Chief Operating Officer. Kieffer, who joined Enanta in 2020, previously served as the Chief Product Strategy Officer. Her new role will focus on operational execution and aligning the company’s strategic priorities.

“After 43 years in the pharmaceutical and biotechnology industries, and 23 years as the Company’s CEO, I have decided that the time is right for me to begin my retirement from full-time executive leadership,” Luly stated. He expressed pride in the company’s accomplishments and excitement about its future pipeline.

Dr. Bruce L. A. Carter, Chairman of the Board, acknowledged Luly’s contributions and leadership during his tenure, particularly in advancing treatments for hepatitis C and other viral infections.

Background

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases. The company is listed on the Nasdaq under the ticker symbol ENTA and operates within the Pharmaceutical Preparations sector (SIC: 2834).

What the Filing Says

The filing states, “On October 28, 2026, Enanta Pharmaceuticals, Inc. announced Dr. Luly’s intention to retire as President and Chief Executive Officer by February 1, 2027.” It also notes the appointment of Dr. Kieffer as COO and the initiation of a search for Luly’s successor.

Impact

This leadership transition may affect employees, stakeholders, and investors as the company navigates its next phase of growth. The strategic direction under new leadership will be closely monitored by industry analysts and competitors.

What's Next

The Board of Directors is actively searching for Dr. Luly’s successor, but the filing does not specify the timeline for this process.